Intersect ENT (XENT) Tops Q3 EPS by 5c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- Wall St tumbles on tech selloff as concerns about hawkish Fed, AI spending mount
- SpaceX extends losses after $600 billion wipeout, tech stocks slide again
- Oil steady as investors focus on Hormuz flows after peace talks
- South Korea leveraged ETF crisis sparks global chip selloff
- Trump announces nuclear deal with Iran, lifts Hormuz blockade
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- 'Equal and opposite': BTIG's Krinsky sees sharp reversal ahead for chip stocks
Leerink Partners Cuts Price Target on Intersect ENT (XENT) to $14; Reiterates Outperform
November 3, 2016 7:41 AM EDTLeerink Partners maintained an Outperform rating on Intersect ENT (NASDAQ: XENT), and cut the price target to $14.00 (from $21.00), following the company's 3Q and sell-off. Revenues of $18.5M beat consensus $17.8M and reflected a second consecutive quarter of y/y sales growth acceleration.
Analyst Richard Newitter commented, "Following XENT's massive... More
